Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Go, RS; Jacobsen, E; Baiocchi, R; Buhtoiarov, I; Butler, EB; Campbell, PK; Coulter, DW; Diamond, E; Flagg, A; Goodman, AM; Goyal, G; Higman, M ...
Published in: J Natl Compr Canc Netw
November 2021
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2021
Volume
19
Issue
11
Start / End Page
1277 / 1303
Location
United States
Related Subject Headings
- Prognosis
- Oncology & Carcinogenesis
- Humans
- Histiocytosis, Sinus
- Histiocytosis, Langerhans-Cell
- Hematologic Neoplasms
- Erdheim-Chester Disease
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Go, R. S., Jacobsen, E., Baiocchi, R., Buhtoiarov, I., Butler, E. B., Campbell, P. K., … Darlow, S. D. (2021). Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(11), 1277–1303. https://doi.org/10.6004/jnccn.2021.0053
Go, Ronald S., Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, et al. “Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 19, no. 11 (November 2021): 1277–1303. https://doi.org/10.6004/jnccn.2021.0053.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, et al. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Nov;19(11):1277–303.
Go, Ronald S., et al. “Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 19, no. 11, Nov. 2021, pp. 1277–303. Pubmed, doi:10.6004/jnccn.2021.0053.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Nov;19(11):1277–1303.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2021
Volume
19
Issue
11
Start / End Page
1277 / 1303
Location
United States
Related Subject Headings
- Prognosis
- Oncology & Carcinogenesis
- Humans
- Histiocytosis, Sinus
- Histiocytosis, Langerhans-Cell
- Hematologic Neoplasms
- Erdheim-Chester Disease
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis